News | January 06, 2026
Wegovy pill marks first GLP-1 weight-loss medicine in oral form
The approval introduces a needle-free alternative to injectable GLP-1 therapies
The approval introduces a needle-free alternative to injectable GLP-1 therapies
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
Enabling a new era in minimally invasive obesity treatment across Europe
Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen is bioequivalent to Victoza Injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
Prior to joining Eris, Ranganathan was Commercial Director, Women's Health, Metabolics, and International Business at Abbott India Limited
Subscribe To Our Newsletter & Stay Updated
